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identifi cation of FOXP1 protein expression, they have used 
JC12, anti-FOXP1 antibody. After immunohistochemical 
staining FOXP1 was detected in majority of normal tissues 
as well as in different tumor tissues. In reactive tonsil 
FOXP1 was present in nuclei of mantle zone B cells, and 
in nucleus of scattered B cells of germinal centers2.
In 2006 Hui Hu et al. published a paper that confi rms 
essential role of Foxp1 in early B cell development and in 
B lymphopoiesis. The experimental mouse model showed 
that Foxp1 protein binds to the Erag enhancer and thus 
impact in specifi c way VDJ recombination of immuno-
globulin heavy chain gene in B-cells3.
In the same year Savarese and Grosschedl showed that 
Foxp1 has an important role in B-cell development through 
infl uence on the expression of RAG genes4.
In B-cell malignancies deregulation of FOXP1 expres-
sion may play an important role in disease development, 
but it is still not clear if it acts as an oncogene or has a 
tumor suppressor function5-9.
Introduction
FOXP1 gene belongs to numerous genes from Fork-
head-box gene family, known to be involved in develop-
ment, organogenesis, and congenital disorders and, as 
well, carcinogenesis. They code for transcriptor factors 
recognizable by characteristic »winged-helix« domain1. The 
FOXP1 gene is located on 3p14.1. Loss of heterozygosity of 
this region, known to harbor tumor suppressor genes, is 
frequent event in a wide range of human tumors. In order 
to investigate expression of the FOXP1 mRNA in human 
tissues, Banham et al. in 2001 used hybridization of the 
FOXP1 cDNA to a human MTE (micro tissue expression) 
array. They have found FOXP1 mRNA in almost all nor-
mal tissues, especially lymphoid and gastrointestinal tis-
sues. FOXP1 mRNA was at that point detected in fetal and 
adult tissues. The same group also compared FOXP1 
mRNA expression in normal and tumor tissues and found 
decreased mRNA levels in most tumor counterparts. For 
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A B S T R A C T
FOXP1 protein was fi rstly analyzed in normal tissues, and afterwards in different tumor tissues, mainly carcinoma 
and lymphoma. In B-cell malignancies, its role was well explored; its expression was shown to be connected with disease 
prognosis in certain B-non Hodgkin lymphomas. In this study, 16 bone marrow trephine samples from patients with no 
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was found to be expressed in 22 cases of MDS and in none of MPD cases. Its expression in MDS was observed mostly in 
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While FOXP1 is thoroughly explored in lymphoprolif-
erative diseases and even became one of the key factors 
for diffuse large B-cell lymphoma prognostic immunohis-
tochemical algorithm10, its presence and role in non-lym-
phoid hematopoesis as well as in myeloproliferative disor-
ders remains unknown.
There are two distinct groups of myeloproliferative dis-
orders: myelodysplastic syndrome (MDS) and myeloprolif-
erative disease (MPD). MDS is a neoplasm that origins 
from the bone marrow stem cell and is characterized by 
ineffective heamtopoesis in one or more cell lines. It is 
considered to be clonal hematopoietic disorder character-
ized by cytopenia and bone marrow dysplasia that eventu-
ally leads to acute myeloid leukemia. Functional abnor-
malities of erythroid, megakaryocytic and granulocytic 
lineages are often seen, while abnormal eosinophils, ba-
sophils and mast cells are quite rare. The classifi cation of 
myelodysplastic syndromes, based on the clinical data and 
biologic characteristics (morphology, immunophenotype, 
cytogenetic and molecular biology) given by the French-
American-British (FAB) group and later by World Health 
Organization (WHO), reveals fi ve main types: refractory 
anaemia (RA), refractory anaemia with ring sideroblasts 
(RARS), refractory anaemia with excess blasts (RAEB), 
refractory anaemia with excess blasts in transformation, 
(RAEB-t) and chronic myelomonocytic leukaemia 
(CMML)11-15. Among MDS patients there is one specifi c 
group: patients that have neoplastic cells harboring a non-
random aberration of deletion between bands q31 and q33 
on chromosome 5. »5q- syndrome« group lacks many genes 
encoding growth factors located on the long arm of chro-
mosome 5. Their clinical behavior is different from other 
MDS patients – they less frequently show progression to 
acute myeloid leukemia16.
On the other hand, MPD is a clonal disorder of multi-
potent hematopoietic progenitors that includes 3 Philadel-
phia chromosome negative (Ph-), phenotypically related 
diseases, and chronic myelogenous leukemia (CML), 
which is mostly Ph+17-20. Polycythemia vera (PV), essential 
thrombocytosis (ET), and chronic idiopathic myelofi brosis 
(CIMF) are all believed to be »closely interrelated« disor-
ders characterized by great numbers of nucleated red cells 
and granulocytes in all stages of maturation with marked 
hyperplasia and clustering of enlarged mature megakary-
ocytes. Described and investigated in 1950. by Dameshek 
W, MPD was suspected to be induced by stimulation of 
unknown factors or lack of the normal inhibitory factors21. 
In 2005 James C et al. confi rmed this hypothesis with 
fi nding of loss of inhibitory activity caused by V617F mu-
tation of JAK2 that leads to trilinear myeloproliferation22. 
Although those fi ndings lead to a possibility of developing 
targeted therapy, better understanding of this entity de-
velopment and signaling pathways of the diseases still 
remain needful.
CML is associated with a characteristic chromosomal 
translocation t(9;22)(q34;q11), called the Philadelphia 
chromosome. This clonal bone marrow stem cell disorder 
represents proliferation of mainly mature myeloid cells. 
In some cases, it can progress through blastic transforma-
tion to acute myeloblastic leukemia and in those cases it 
is associated with an extremely high mortality23-25. For 
CML targeted therapy already exists: few different drugs 
that inhibit tyrosine kinase (abnormal BCR-ABL protein 
which is a result of t(9;22)(q34;q11)) are constructed, i.e. 
imatinib. Such drugs are well-tolerated, but there are 
some patient groups in which they are toxic and therefore 
any new insight in factors that contribute to CML course 
is still notable26,27.
In this study, based on FOXP1 relevance for different 
tissues development and its regulatory function in lym-
phocytes, we sought to determine whether it is also ex-
pressed in non-lymphoid haematopoietic cells of bone mar-
row as well as in their neoplastic myeloid counterparts.
Material And Methods
Bone marrow FFPE trephine samples from 16 patients 
with no hematopoietic malignancies and 10 peripheral 
blood smears from healthy individuals were morphologi-
cally reviewed and immunostained with anti-FOXP1 an-
tibody (JC12 antibody, acquired from Dr Alison Banham, 
Oxford, UK).
Additionaly FFPE bone marrow trephine samples from 
60 patients with myeloid disorders were also immunos-
tained with anti-FOXP1 antibody: 25 patients with MDS 
(6 refractory anemia with excess blasts, 8 refractory ane-
mia, 8 refractory cytopenia with multilineage dysplasia, 
3 5q deletion syndrome MDS), 29 with MPD Ph (10 es-
sential thrombocythemia, 8 polycythemia vera and 11 
chronic idiopathic myelofi brosis) and 6 with CML.
All cases were, after the examination of immunostaing 
of FOXP1 protein by pathologists (EL, KH, MD), double 
stained. Anti-glycophorin C (Dako, Glostrup, Denmark) 
and anti-myeloperoxidase antibodies (Dako) were used for 
double labeling along with JC12 antibody for detection of 
erythropoietic and myelopoietic cells, respectively. Reactive 
tonsil sections were used as controls in each round of stain-
ing. Small, round B-lymphocytes present in all bone mar-
row samples were considered internal positive controls.
Immunohistochemical double staining was performed 
on 4 µm tick, formalin fi xed paraffi n embedded bone mar-
row trephine sections according to the protocol provided 
by the manufacturer of the visualization LSAB/HRP kit 
(Dako) using two different chromogens: DAB chromogen 
(Dako) for nuclear staining and Vector SG chromogen 
(Vector Laboratories Inc., Burlingame, CA) for membrane 
staining.
Triple blind reading was performed for all samples.
This study is a part of a research project approved by 
the Ethics Committee of the Zagreb University School of 
Medicine.
Results
Bone marrow trephine samples from all 16 patients 
with no hematopoietic malignancies showed nuclear posi-
tivity after staining with JC12 antibody in 60-80% of 
small to middle sized cells that occur in islands. Those 
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cells were also immunohistochemicaly positive for anti-
glycophorin C antibody. (Figure 1a)
Same samples showed nuclear positivity after staining 
with JC12 antibody in 79-85% of large cells with regular 
nuclei, abundant cytoplasm which were immunohisto-
chemicaly also positive after staining with anti-myeloper-
oxidase antibody. (Figure 1b)
Small, round cells with dark large nucleus and small 
amount of cytoplasm that are diffusely scattered through 
the interstitium of the bone marrows were, according to 
their morphology, considered B-lymphocytes. Those cells 
show ed JC12 staining, but were negative for anti-glycoph-
orine C and anti-myeloperoxidase antibodies. (Figures 1c 
and d).
All peripheral blood smears from healthy individuals 
showed JC12 staining in nucleus of small, round cells that 
correspond to lymphocytes. Morphologically recognizable 
erythrocytes, granulocytes and agranulaocytes were neg-
ative after immnostaing with JC12 antibody.
Bone marrow samples from patients with MDS showed 
versatile FOXP1 positivity. Half cases (3/6) of refractory 
anemia with excess blasts showed JC12 staining in my-
eloperoxidase positive cells and the other half had no my-
eloperoxidase or glycophorine C positive cells with expres-
sion of FOXP1. All refractory anemia cases showed 
FOXP1 positivity in cells also positive for myeloperoxi-
dase. All 8 cases of refractory cytopenia with multilineage 
dysplasia showed FOXP1 expression in myeloperoxidase 
positive cells. Only one of those cases showed FOXP1 ex-
pression not only in myeloperoxidase, but as well in gly-
cophorine C positive cells. Only one of 5q- syndrome MDS 
cases had confi rmed deletion of 5q region, while for the 
Fig. 1. Immunohistochemical staining in cells of non-tumor bone marrow trephine sections a) cells that express both glycophorin C 
and FOXP1 b) cells that express both myeloperoxidase and FOXP1 c) cells that express FOXP1 but lack glycophorin C expression and 
d) cells that express FOXP1 but lack myeloperoxidase expression.
Fig. 2. Immunohistochemical staining in cells of 5q- syndrome MDS bone marrow trephine sections a) cells that express both 
glycophorin C and FOXP1 b) cells that express both myeloperoxidase and FOXP1.
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other two clinical data were not available and therefore 
their diagnosis was based only on morphology suspicion. 
One of those unconfi rmed 5q- cases showed FOXP1 ex-
pression in myeloperoxidase positive cells, while the other 
showed FOXP1 expression in glycophorine C positive cells. 
The only confi rmed 5q- syndrome MDS case showed JC12 
staining in both glycophorine C and myeloperoxidase 
positive cells. (Figures 2a and b).
Bone marrow samples from all patients with MPD and 
CML showed no FOXP1 staining in myeloperoxidase or 
glycophorine C positive cells.
Discussion
FOXP1 expression was detected by immunohistochem-
ical staining in 16 non-lymphoid haematopoietic bone mar-
row trephines. Positive staining was detected not only in 
small, round cells with compact large nucleus and little 
cytoplasm – cells believed to represent lymphocytes, but 
also in middle sized cells that occur in islands and large 
cells with regular nuclei and abundant cytoplasm. Those 
cells that were unexpectedly immunohistochemically 
positive for JC12 antibody were also positive for glycopho-
rin C and myeloperoxidase, respectively, suggesting that 
they might represent developmental stages of erythroid 
and myeloid lineages. JC12 immunostaing of peripheral 
blood smears from healthy individuals served as a control 
of FOXP1 expression in fi nal developmental stages of ery-
throid and myeloid lineages: erythrocytes, granulocytes 
and agranulocytes. They all lack FOXP1 expression.
As FOXP1 is a transcriptor factor known to be ex-
pressed in different fetal and adult tissues, thus possibly 
involved in development of different types of cells2, this 
fi nding might suggest that FOXP1 is needed for hemato-
poiesis in developmental stages of all lineages.
We have used bone marrow trephine sections of sam-
ples taken from patients without hematopoietic malignan-
cies. Question remains if those cells are representative 
and if they can be regarded as »normal« or »healthy«. Still, 
JC12 immunohistochemically positive cells stained with 
anti-glycophorin C and anti-myeloperoxidase antibodies 
can not be disregarded.
FOXP1 is also known to be present in different tumors. 
Depending on type of tumor cells it shows overexpression, 
lack of expression or cytoplasmatic expression2. Its role in 
B-cell non Hodgkin lymphoma development and prognosis 
is well explored. Not only that its expression is associated 
with prognosis in diffuse large B-cell lymphoma, but 
FOXP1 gene aberrations were found in cells of mucosa 
associated lymphoma as well as in diffuse large B-cell 
lymphoma5-7,9,28-30.
Our results show presence of FOXP1 protein in MDS, 
but not MPD cells. Based on their cells of origin, this data 
could imply that neoplasms derived from earlier develop-
mental stages of myeloid linages need FOXP1 for their 
progression. This fi nding also suggests that FOXP1 re-
mains important in myeloid cells even after the initial 
oncogenic events of these disorders. Interestingly, only two 
cases showed FOXP1 in both myeloperoxidase and gly-
cophorin C positive cells. 5q- syndrome MDS case and 
refractory cytopenia with multilineage dysplasia case 
showed two different types of tumor cells that express 
FOXP1 transcription factor. As both disorders are derived 
from bone marrow stem cell, retained FOXP1 expression 
in two lineages is not unexpected, although it could sug-
gest that those entities are not so distinct as it is believed. 
In case of refractory cytopenia with multilineage dyspla-
sia expression of same transcription factor in more than 
one lineage can be hypothesized. 7 other cases of refrac-
tory cytopenia with multilineage dysplasia show uniform 
lack of FOXP1 expression indicating similar oncogenic 
pathways in all affected cell types. 5q- syndrome MDS 
case, being the only one with cytogenetic confi rmation of 
the diagnosis in the study, suggests that chromosome 5 in 
this case lacks genes responsible for differentiation of com-
mon myeloid progenitor to proerytroblast and myeloblasts.
Conclusion
Taken together our results demonstrate that FOXP1 
is not only present in normal development stages of ery-
throid and myeloid lineages but that it could also have 
maintained role in tumors that arise from their earlier 
stages. Tumors derived from later developmental stages 
of myeloid lineage show lack of FOXP1 expression thus 
revealing oncogenic events that do not include this tran-
scription factor.
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EKSPRESIJA FOXP1 U NORMALNIM I NEOPLASTIČNIM STANICAMA ERITROIDNE I MIJELOIDNE 
LOZE
S A Ž E T A K
Protein FOXP1 prvo je bio istraživan u normalnom tkivu i različitim tumorskim tkivima, najviše karcinomima i 
limfomima. Njegova je uloga u B-staničnim neoplazmama dobro istražena, a dokazano je i da je njegova ekspresija u 
pojedinim B ne-Hodgkinovim limfomima vezana za prognozu. U ovom istraživanju 16 uzoraka biopsija koštanih srži 
uklopljenih u parafi n pacijanata bez hematoloških bolesti i 10 uzoraka razmaza periferne krvi zdravih ispitanika, imu-
nohistokemijski su obojeni anti-FOXP1 antitijelom. Pozitivne stanice u koštanim sržima nisu bili samo limfociti, već i 
stanice koje su imunohistokemijski pozitivne i na glikoforin C ili mijeloperoksidazu. Uzorci razmaza periferne krvi nisu 
pokazivali druge pozitivne stanice osim malih, okruglih limfocita. Dodatno je analizirano 60 uzoraka koštanih srži 
pacijenata s neoplazmama mijeloidne linije. 25 uzoraka bilo je od pacijenata s mijelodisplastičnim sindromom (MDS), a 
35 s mijeloproliferativnom bolesti (MPD). Svi su uzorci obojeni dvostrukim imunohistokemijskim bojenjem korištenjem 
anti-FOXP1/anti-glikoforin C i anti-FOXP1/anti-mijeloperoksidaza antitijela. FOXP1 nađen je u neoplastičnim stani-
cama 22 uzorka MDS-a, dok tumorske stanice MPD-a nisu pokazivale njegovu ekspresiju. Neoplastične MDS stanice 
koje eksprimiraju FOXP1 većinom su bile pozitivne i na mijeoperoksidazu. Samo su dva uzorka pokazala ekspresiju 
FOXP1 proteina i u stanicama pozitivnim na glikoforin C i u stanicama pozitivnim na mijeloperoksidazu. Ovakvi re-
zultati pokazuju prisutnost FOXP1 proteina u normalnim razvojnim stadijima eritroidne i mijeloidne loze i ukazuju na 
mogućnost da je on potreban za razvoj svih hematopoetskih stanica. Isto tako ukazuju na mogućnost da FOXP1 ima 
ulogu u razvoju mijeloidnih neoplazmi.
